JPH027942B2 - - Google Patents
Info
- Publication number
- JPH027942B2 JPH027942B2 JP16145281A JP16145281A JPH027942B2 JP H027942 B2 JPH027942 B2 JP H027942B2 JP 16145281 A JP16145281 A JP 16145281A JP 16145281 A JP16145281 A JP 16145281A JP H027942 B2 JPH027942 B2 JP H027942B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- chloroform
- general formula
- under reduced
- reduced pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 nitrate ester Chemical class 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000019188 sodium D-pantothenate Nutrition 0.000 description 1
- 239000011756 sodium D-pantothenate Substances 0.000 description 1
- NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は新規硝酸エステル誘導体に関するもの
である。
本発明の化合物は一般式()
〔式中R1は水素原子又はニトロ基を、R2は炭
素数1〜6のω―(ニトロオキシ)アルキル基も
しくは炭素数2〜7のω―(カルボキシ)アルキ
ル基または一般式()
(式中R1は前記に同じ。)で表わされる基を示
す。〕で表わされ、血管拡張作用を呈することか
ら循環器系治療剤のなかでも虚血性心疾患治療薬
として有用である。
本発明の化合物は、次の一般式()
(式中R3はω―ハイドロキシアルキル基また
はω―カルボキシアルキル基のアルカリ金属塩も
しくはアルカリ土類金属塩を示す。)で表わされ
るアルコール誘導体を発煙硝酸中、低温で反応さ
せて製造することが出来る。一方、一般式()
のR2が一般式()で示される基である硝酸エ
ステルは上記の製造法で得られた一般式()
(式中R1は前記に同じ。)で表わされる化合物
を、テトラヒドロフラン、クロロホルム、ジクロ
ロメタン等の溶媒中、トリエチルアミン存在下、
クロル炭酸アルキルと反応せしめ、混合酸無水物
とし、続いてシスタミンと反応させることにより
製造することが出来る。
かくして製された本発明化合物の代表的化合物
であるパンテノール三硝酸エステルの冠血管拡張
作用について、ライフサイエンス23巻1609頁、
1978年(今井昭一等)に記載の方法に準じ、モル
モツト摘出心臓標本にてランゲンドルフ氏法によ
り30μg投与時の冠血管潅流量を検討した結果、
上記本発明化合物がニトログリセリン投与時の冠
血管血流量増加作用の約70%の活性を呈すること
を確認した。
以下、本発明を実施例により説明する。
実施例 1
D―パンテノール3.0gを氷酢酸4mlに溶かした
溶液を、氷水浴中、0〜2℃に冷却した発煙硝酸
(比重1.52)25ml中に滴下する。滴加した後、更
に3.5時間、0〜5℃にて撹拌した後、氷水100ml
中に注加する。得られた水溶液をクロロホルムに
て抽出する。抽出液を水洗し、無水硫酸ナトリウ
ムで乾燥後、減圧下に濃縮する。得られた油状物
の残渣をシリカゲル50gを用いてカラムクロマト
を行ない、クロロホルムにて溶出し、シリカゲル
薄層クロマト〔展開溶媒:クロロホルム―イソプ
ロピルエーテル(1:1)の混合物〕にてRf値
約0.7のスポツトを認めるフラクシヨンを集め、
減圧下に濃縮すれば無色プリズム晶のパンテノー
ル三硝酸エステル2.43gを得る。
融点 54.5〜56℃
NMR(CDCl3,90MHz)δppm:
1.19,1.21(各々3H,s,―CH3 )
2.01(2H,m,―CH2CH2 CH2―)
3.46(2H,q,―NHCH2 CH2―)
4.45(2H,s,
The present invention relates to novel nitrate ester derivatives. The compound of the present invention has the general formula () [In the formula, R 1 is a hydrogen atom or a nitro group, R 2 is an ω-(nitrooxy)alkyl group having 1 to 6 carbon atoms, an ω-(carboxy)alkyl group having 2 to 7 carbon atoms, or a general formula () (In the formula, R 1 is the same as above.) ] and exhibits a vasodilatory effect, making it useful as a therapeutic agent for ischemic heart disease among cardiovascular system therapeutic agents. The compound of the present invention has the following general formula () (In the formula, R 3 represents an alkali metal salt or an alkaline earth metal salt of an ω-hydroxyalkyl group or an ω-carboxyalkyl group.) It can be produced by reacting an alcohol derivative represented by the following in fuming nitric acid at a low temperature. I can do it. On the other hand, the general formula ()
The nitric acid ester in which R 2 is a group represented by the general formula () has the general formula () obtained by the above production method. (In the formula, R 1 is the same as above.) In a solvent such as tetrahydrofuran, chloroform, dichloromethane, etc., in the presence of triethylamine,
It can be produced by reacting with an alkyl chlorocarbonate to form a mixed acid anhydride, and then reacting with cystamine. Regarding the coronary vasodilator effect of panthenol trinitrate, which is a representative compound of the compound of the present invention thus prepared, Life Science Vol. 23, p. 1609,
According to the method described in 1978 (Shoichi Imai et al.), we investigated the coronary vascular perfusion rate when 30 μg was administered using Langendorff's method using isolated heart specimens from guinea pigs.
It was confirmed that the above-mentioned compound of the present invention exhibits approximately 70% of the activity of increasing coronary blood flow when nitroglycerin is administered. The present invention will be explained below using examples. Example 1 A solution of 3.0 g of D-panthenol dissolved in 4 ml of glacial acetic acid is added dropwise to 25 ml of fuming nitric acid (specific gravity 1.52) cooled to 0-2°C in an ice-water bath. After the dropwise addition, the mixture was further stirred for 3.5 hours at 0 to 5°C, and then added with 100 ml of ice water.
Pour inside. The resulting aqueous solution is extracted with chloroform. The extract is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting oily residue was subjected to column chromatography using 50 g of silica gel, eluted with chloroform, and silica gel thin layer chromatography [developing solvent: chloroform-isopropyl ether (1:1) mixture] to obtain an Rf value of approximately 0.7. Collect the flux that recognizes the spot,
Concentration under reduced pressure yields 2.43 g of colorless prismatic panthenol trinitrate. Melting point 54.5-56℃ NMR (CDCl 3 , 90MHz) δppm: 1.19, 1.21 (3H, s, -CH 3 respectively) 2.01 (2H, m, -CH 2 CH 2 CH 2 -) 3.46 (2H, q, ―NHC H 2 CH 2 ―) 4.45 (2H, s,
【式】) 4.53(2H,t,―CH2CH2 ONO2) 5.13(1H,s,[Formula]) 4.53 (2H, t, - CH 2 C H 2 ONO 2 ) 5.13 (1H, s,
【式】)
6.56(1H,br,―CONH―)
元素分析(%) C9H16N4O10として
計算値 C31.77,H 4.74,N 16.47
実測値 C31.56,H 4.33,N 16.44
上記シリカゲルカラムクロマトをさらにクロロ
ホルム―アセトン(1:1)の混合溶媒で溶出
し、シリカゲル薄層クロマトにてRf値約0.4を示
すフラクシヨンを合わせ、減圧下に濃縮して無色
油状物としてN―(4―ニトロオキシ―3,3―
ジメチル―2―ハイドロキシブチル)―3―アミ
ノプロピルナイトレート0.8gを得る。
NMR(CDCl3,90MHz)δppm:
1.05,1.07(各々3H,s,―CH3 )
2.00(2H,m,―CH2CH2 CH2―)
3.43(2H,q,―NHCH2 CH2―)
4.01(1H,s,[Formula]) 6.56 (1H, br, -CON H -) Elemental analysis (%) As C 9 H 16 N 4 O 10 Calculated value C31.77, H 4.74, N 16.47 Actual value C31.56, H 4.33, N 16.44 The above silica gel column chromatography was further eluted with a mixed solvent of chloroform-acetone (1:1), and the fractions showing an Rf value of about 0.4 in the silica gel thin layer chromatography were combined and concentrated under reduced pressure to form a colorless oily N- (4-nitrooxy-3,3-
0.8 g of dimethyl-2-hydroxybutyl)-3-aminopropyl nitrate is obtained. NMR (CDCl 3 , 90MHz) δppm: 1.05, 1.07 (3H, s, -CH 3 respectively) 2.00 (2H, m, -CH 2 CH 2 CH 2 -) 3.43 (2H, q, -NHC H 2 CH 2 ―) 4.01 (1H, s,
【式】) 4.45(2H,s,【formula】) 4.45(2H,s,
【式】)
4.55(2H,t,―CH2CH2 ONO2)
7.13(1H,br,―CONH―)
実施例 2
D―パントテン酸ナトリウム3.0gを1〜3℃に
冷却した発煙硝酸(比重1.52)21ml中に少量づつ
加える。加え終つた後、更に2〜5℃にて3時間
撹拌する。その後、反応液を氷水150ml中に注加
し、酢酸エチルにて抽出する。酢酸エチル層を水
洗し、無水硫酸ナトリウムで乾燥後、減圧下に濃
縮する。残留する油状物をシリカゲル35gを用い
てカラムクロマトを行なう。クロロホルム500ml
を流した後、クロロホルム―メタノール(20:
1)の混合溶媒にて溶出し、得られたフラクシヨ
ンを減圧下に濃縮して無色油状物のパントテン酸
二硝酸エステル3.5gを得る。
NMR(CDCl3,90MHz)δppm:
1.16,1.18(各々3H,s,―CH3 )
2.64(2H,t,―CH2CH2 COOH)
3.60(2H,q,―NHCH2 CH2―)
4.41(2H,s,[Formula]) 4.55 (2H, t, - CH 2 C H 2 ONO 2 ) 7.13 (1H, br, - CON H -) Example 2 Fuming nitric acid in which 3.0 g of sodium D-pantothenate was cooled to 1 to 3°C (Specific gravity 1.52) Add little by little to 21ml. After the addition is complete, the mixture is further stirred at 2 to 5°C for 3 hours. Thereafter, the reaction solution was poured into 150 ml of ice water and extracted with ethyl acetate. The ethyl acetate layer is washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The remaining oil is subjected to column chromatography using 35 g of silica gel. Chloroform 500ml
After flushing, chloroform-methanol (20:
Elute with the mixed solvent of 1) and concentrate the obtained fraction under reduced pressure to obtain 3.5 g of pantothenic acid dinitrate as a colorless oil. NMR (CDCl 3 , 90MHz) δppm: 1.16, 1.18 (3H, s, -CH 3 respectively) 2.64 (2H, t, -CH 2 CH 2 COOH) 3.60 (2H, q, -NHC H 2 CH 2 - ) 4.41(2H,s,
【式】) 5.10(1H,s,【formula】) 5.10 (1H, s,
【式】)
7.00(1H,br,―CONH―)
10.1(1H,br,―COOH)
実施例 3
実施例2で得られたパントテン酸二硝酸エステ
ル2.5gをトリエチルアミン1.1gとテトラヒドロフ
ラン20mlの混液中に溶かし、氷水浴中で冷却す
る。これにクロル炭酸エチル0.88gとテトラヒド
ロフラン8mlの混液を滴加した後、3〜5℃にて
1.5時間撹拌する。この溶液にシスタミン・二塩
酸塩0.91g、トリメチルアミン1.8g、テトラヒド
ロフラン20mlの混合液を滴加した後、3〜5℃に
て2時間撹拌する。反応溶液を減圧下に濃縮し、
残渣にクロロホルム100mlを加え撹拌する。この
溶液を2N―水酸化ナトリウム水溶液、希塩酸、
水にて順次洗浄した後、無水硫酸ナトリウムで乾
燥し、減圧下に濃縮して得られる油状物をシリカ
ゲル40gを用いてカラムクロマトを行なう。クロ
ロホルム―メタノール(20:1)の混合溶媒にて
溶出し、目的物を含有するフラクシヨンを合わせ
減圧濃縮して得られる残渣をクロロホルム―エー
テル混液より再結晶して無色粉末のパンテチン四
硝酸エステル1.02gを得る。
融点 104〜108℃
NMR(CDCl3,90MHz)δppm:
1.18(12H,s,―CH3 ×4)
2.50(4H,m,―CH2CH2 CONH―×2)
2.83(4H,m,―CH2 ―S―S―CH2 ―)
3.60(8H,m,―CONH―CH2 CH2−×4)
4.41(4H,s,[Formula]) 7.00 (1H, br, -CON H -) 10.1 (1H, br, -COO H ) Example 3 2.5 g of pantothenic acid dinitrate obtained in Example 2 was mixed with 1.1 g of triethylamine and 20 ml of tetrahydrofuran. Dissolve in mixture and cool in an ice-water bath. A mixture of 0.88 g of ethyl chlorocarbonate and 8 ml of tetrahydrofuran was added dropwise to this, and the mixture was heated at 3 to 5°C.
Stir for 1.5 hours. A mixed solution of 0.91 g of cystamine dihydrochloride, 1.8 g of trimethylamine, and 20 ml of tetrahydrofuran was added dropwise to this solution, followed by stirring at 3 to 5°C for 2 hours. The reaction solution was concentrated under reduced pressure,
Add 100 ml of chloroform to the residue and stir. This solution was mixed with 2N sodium hydroxide aqueous solution, dilute hydrochloric acid,
After sequentially washing with water, drying over anhydrous sodium sulfate and concentrating under reduced pressure, the resulting oily substance was subjected to column chromatography using 40 g of silica gel. Elute with a mixed solvent of chloroform-methanol (20:1), combine the fractions containing the target product, concentrate under reduced pressure, and recrystallize the resulting residue from a chloroform-ether mixture to obtain 1.02 g of pantethine tetranitrate as a colorless powder. get. Melting point 104-108℃ NMR (CDCl 3 , 90MHz) δppm: 1.18 (12H, s, -CH 3 × 4) 2.50 (4H, m, -CH 2 CH 2 CONH - × 2) 2.83 (4H, m, -C H 2 -S-S-C H 2 -) 3.60 (8H, m, -CONH-C H 2 CH 2 -×4) 4.41 (4H, s,
【式】) 5.07(2H,s,【formula】) 5.07(2H,s,
【式】) 6.90,7.60(各々2H,br,―CONH−×2) 元素分析値(%) C22H38N8O16S2として 計算値 C 35.96,H 5.21,N 15.25 実測値 C 35.93,H 5.26,N 14.96[Formula]) 6.90, 7.60 (2H, br, - CON H - x 2 respectively) Elemental analysis value (%) Calculated value as C 22 H 38 N 8 O 16 S 2 C 35.96, H 5.21, N 15.25 Actual value C 35.93, H 5.26, N 14.96
Claims (1)
素数1〜6のω―(ニトロオキシ)アルキル基若
しくは炭素数2〜7のω―(カルボキシ)アルキ
ル基又は一般式 (式中R1は前記に同じ。)で表される基を示
す。]で表わされる硝酸エステル誘導体。[Claims] 1. General formula [In the formula, R 1 is a hydrogen atom or a nitro group, R 2 is an ω-(nitrooxy)alkyl group having 1 to 6 carbon atoms, an ω-(carboxy)alkyl group having 2 to 7 carbon atoms, or a general formula (In the formula, R 1 is the same as above.) ] A nitrate ester derivative represented by.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16145281A JPS5862147A (en) | 1981-10-09 | 1981-10-09 | Nitric acid ester derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16145281A JPS5862147A (en) | 1981-10-09 | 1981-10-09 | Nitric acid ester derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5862147A JPS5862147A (en) | 1983-04-13 |
JPH027942B2 true JPH027942B2 (en) | 1990-02-21 |
Family
ID=15735366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16145281A Granted JPS5862147A (en) | 1981-10-09 | 1981-10-09 | Nitric acid ester derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5862147A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5284872A (en) * | 1989-09-12 | 1994-02-08 | Schwarz Pharma Ag | Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof |
IL120531A (en) * | 1997-03-26 | 2006-12-31 | Yissum Res Dev Co | Nitric oxide donors and pharmaceutical compositions containing them |
-
1981
- 1981-10-09 JP JP16145281A patent/JPS5862147A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5862147A (en) | 1983-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06135948A (en) | Styrene derivative or its salt | |
US4863926A (en) | Nitro aliphatic compounds, process for preparation thereof and use thereof | |
JPH027942B2 (en) | ||
US5233041A (en) | Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone from a 2,3-unsaturated-1-cyclopentanylpurinone | |
JPS61155346A (en) | Alkoxymethyl ether and alkoxymethyl ester derivative | |
JPS60181056A (en) | Preparation of n-(4-(3-aminopropylaminobutyl)-2,2- dihydroxyethanamide | |
TWI812679B (en) | Process for preparing soluble guanylate cyclase stimulators | |
EP0713865B1 (en) | 2-Aminobenzenesulphonic acid and 2-aminobenzenesulphonyl chloride derivatives, their preparation and their use as synthetic intermediates | |
JP2684749B2 (en) | Bis- (4-fluoro-2-chlorophenyl) disulfide derivative | |
US4454336A (en) | Derivatives of 3-(formylmethylthio)-propanoate | |
US4780542A (en) | Process for the synthesis of esters and amides of carboxylic acids | |
JPH04217650A (en) | Production of acid addition salt of delta-amino-levulinic acid | |
US4866197A (en) | Production of N-((2-alkoxy-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)carbonyl)-N-methylglycine esters | |
US4376734A (en) | Process for 3-amino-steroid preparation | |
JPS6139957B2 (en) | ||
FR2693197A1 (en) | New phenyl-quinolinyl-methyl-imidazo-pyridine derivs. - useful as angiotensin (II) antagonists for treating hypertension, glaucoma, etc. | |
JPH013194A (en) | 2'-Bromo-2',3'-didehydro-2',3'-dideoxycytidine and its production method | |
US4914243A (en) | Production of 2-alkoxy or aryl(lower)alkoxy-6-methoxy-1-naphthalenecarboxaldehyde | |
KR950006149B1 (en) | Novel n-(2-haloalkanoyloxy)succinimide derivative and manufacturing method thereof | |
JP3481963B2 (en) | Method for producing organic germanium compound | |
JPS59157097A (en) | Alpha,alpha-trehalose fatty acid tetraester derivative and its preparation | |
JPS60166680A (en) | Preparation of swainsonine | |
JPS6124568A (en) | Preparation of dihydropyridine ester | |
JPH0119384B2 (en) | ||
JPH0543603A (en) | (galactopyranosyl)cyclomaltheptaose, preparation thereof, and intermediate therefor |